Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Add as a preferred source on Google
BRIDGEWATER, N.J., May 08, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today that the Company is scheduled to present at the 18th Annual B. Riley Co. Investor Conference.
| Event: | 18th Annual B. Riley Co. Investor Conference |
| Format: | Presentation and One-on-One Meetings |
| Date: | Wednesday, May 24, 2017 |
| Time: | 1:00pm PT |
| Location: | Santa Monica, CA |
An audio webcast of the Company’s presentation will be available by visiting the investor relations section of the Valeritas website at www.valeritas.com. Replays of the presentation will be available for 90 days.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group 646-536-7030 / 7017 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas The Ruth Group 508-280-6592 [email protected]
